An Open Label Study of STR04 in Participants With Amyotrophic Lateral Sclerosis
Latest Information Update: 23 Dec 2025
At a glance
- Drugs STR 04 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Sponsors New England Cell Therapeutics
Most Recent Events
- 18 Dec 2025 Status changed from recruiting to discontinued. (organizational restructure)
- 17 Sep 2025 Planned End Date changed from 30 Nov 2027 to 30 Jan 2028.
- 17 Sep 2025 Status changed from not yet recruiting to recruiting.